IP Library › Patent Application 15354244
Patent Application
App. No. 15/354,244

Morphinan Derivatives with High Oral Bioavailability

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/354,244
Abstract

The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.

Claims (22)

1 A method of treating a mental illness associated with opioid receptor activity or blockade comprising orally administering a compound of formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof to a subject in need thereof, wherein said compound is administered in a daily dosage of about 1.5 mg/day to about 5 mg/day.

2 . The method according to claim 1 , wherein the mental illness is depression.

3 . The method according to claim 1 , wherein the daily dosage is about 1 mg/day.

4 . The method according to claim 1 , wherein the daily dosage is about 1.5 mg/day.

5 . The method according to claim 1 , wherein the daily dosage is about 2 mg/day.

6 . The method according to claim 1 , wherein the daily dosage is about 3 mg/day.

7 . The method according to claim 2 , wherein the daily dosage is about 1 mg/day.

8 . The method according to claim 2 , wherein the daily dosage is about 1.5 mg/day.

9 . The method according to claim 2 , wherein the daily dosage is about 2 mg/day.

10 . The method according to claim 2 , wherein the daily dosage is about 3 mg/day.

11 . A method of treating a mental illness associated with opioid receptor activity or blockade comprising orally administering a compound of formula:

or a pharmaceutically acceptable salt, ester or prodrug thereof to a subject in need thereof, wherein said compound is administered in a daily dosage of less than 5 mg/day.

12 . The method according to claim 11 , wherein the mental illness is depression.

13 . The method according to claim 11 , wherein the daily dosage is about 1 mg/day.

14 . The method according to claim 11 , wherein the daily dosage is about 1.5 mg/day.

15 . The method according to claim 11 , wherein the daily dosage is about 2 mg/day.

16 . The method according to claim 11 , wherein the daily dosage is about 3 mg/day.

17 . The method according to claim 12 , wherein the daily dosage is about 1 mg/day.

18 . The method according to claim 12 , wherein the daily dosage is about 1.5 mg/day.

19 . The method according to claim 12 , wherein the daily dosage is about 2 mg/day.

20 . The method according to claim 12 , wherein the daily dosage is about 3 mg/day.

Assignments (1)
SECURITY INTEREST Recorded Apr 4, 2017
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 041846/0029 →